-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March:

  • Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 11:10 am (EST)
  • Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 9:20 am (EST)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Incyte Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts

Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa...

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco...

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026...
Back to Newsroom